File Download
 
 
Supplementary

Conference Paper: Phase I/II double-blind, randomized, placebo-controlled study of the novel anti-HBV agent LB80380/ANA380 in patients with chronic HBV infection.
  • Basic View
  • Metadata View
  • XML View
TitlePhase I/II double-blind, randomized, placebo-controlled study of the novel anti-HBV agent LB80380/ANA380 in patients with chronic HBV infection.
 
AuthorsYuen, RMF
Kim, J
Averett, D
Wong, DKH
Kim, CR
Kerr, B
Ngai, WS
Yuen, JCH
Lai, CL
 
Issue Date2004
 
Citation55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, USA 29 Oct-2 Nov 2004 (Published in Hepatology), v. 40 n. 4 Suppl 1, p. 172A [How to Cite?]
 
DC FieldValue
dc.contributor.authorYuen, RMF
 
dc.contributor.authorKim, J
 
dc.contributor.authorAverett, D
 
dc.contributor.authorWong, DKH
 
dc.contributor.authorKim, CR
 
dc.contributor.authorKerr, B
 
dc.contributor.authorNgai, WS
 
dc.contributor.authorYuen, JCH
 
dc.contributor.authorLai, CL
 
dc.date.accessioned2010-09-25T20:46:18Z
 
dc.date.available2010-09-25T20:46:18Z
 
dc.date.issued2004
 
dc.identifier.citation55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, USA 29 Oct-2 Nov 2004 (Published in Hepatology), v. 40 n. 4 Suppl 1, p. 172A [How to Cite?]
 
dc.identifier.hkuros105328
 
dc.identifier.issue4 Suppl 1
 
dc.identifier.spage172
 
dc.identifier.urihttp://hdl.handle.net/10722/102824
 
dc.identifier.volume, v. 40 n. 4 Suppl 1
 
dc.languageeng
 
dc.relation.ispartof55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, USA 29 Oct-2 Nov 2004 (Published in Hepatology)
 
dc.titlePhase I/II double-blind, randomized, placebo-controlled study of the novel anti-HBV agent LB80380/ANA380 in patients with chronic HBV infection.
 
dc.typeConference_Paper
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Yuen, RMF</contributor.author>
<contributor.author>Kim, J</contributor.author>
<contributor.author>Averett, D</contributor.author>
<contributor.author>Wong, DKH</contributor.author>
<contributor.author>Kim, CR</contributor.author>
<contributor.author>Kerr, B</contributor.author>
<contributor.author>Ngai, WS</contributor.author>
<contributor.author>Yuen, JCH</contributor.author>
<contributor.author>Lai, CL</contributor.author>
<date.accessioned>2010-09-25T20:46:18Z</date.accessioned>
<date.available>2010-09-25T20:46:18Z</date.available>
<date.issued>2004</date.issued>
<identifier.citation>55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, USA 29 Oct-2 Nov 2004 (Published in Hepatology), v. 40  n. 4 Suppl 1, p. 172A</identifier.citation>
<identifier.uri>http://hdl.handle.net/10722/102824</identifier.uri>
<language>eng</language>
<relation.ispartof>55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, USA 29 Oct-2 Nov 2004 (Published in Hepatology)</relation.ispartof>
<title>Phase I/II double-blind, randomized, placebo-controlled study of the novel anti-HBV agent LB80380/ANA380 in patients with chronic HBV infection.</title>
<type>Conference_Paper</type>
<identifier.hkuros>105328</identifier.hkuros>
<identifier.volume>, v. 40  n. 4 Suppl 1</identifier.volume>
<identifier.issue>4 Suppl 1</identifier.issue>
<identifier.spage>172</identifier.spage>
</item>